ChunYao Huang

ChunYao Huang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2026 in Materials Today Bio
Verified
Journal Article
Open access
YGYu Guo
Yu Guo
CHChunYao Huang
ChunYao Huang
LXLihua Xu
Lihua Xu
YXYujing Xuan
Yujing Xuan
PWPengju Wang
Pengju Wang
Oncolytic viruses (OVs) represent an emerging cancer therapeutic modality with dual functions of direct tumor cell lysis and activation of systemic antitumor immunity. However, the systemic delivery of OVs remains a significant challenge owing to immune barriers and the immunosuppressive tumor microenvironment (TME). Current delivery strategies can be broadly categorized into naked virus delivery and vector-based delivery. Each platform presents distinct advantages in enhancing delivery efficiency and antitumor immune activation, yet both share common challenges, including immune clearance and delivery stability. In this review, we provide a comprehensive summary of the advantages and limitations associated with these different delivery strategies. In summary, combining OVs with advanced delivery systems holds great promise for advancing personalized and precise cancer therapies. Future research should focus on the development of multifunctional platforms, the optimization of combination treatment regimens, and the establishment of regulatory frameworks to accelerate the clinical translation of OV-based therapies.

30 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CHChunYao Huang
ChunYao Huang
XLXinyi Lu
Xinyi Lu
RXRui Xi
Rui Xi
FDFeiyang Duan
Feiyang Duan
SCShi Cheng
Shi Cheng
JHJun Huang
Jun Huang
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) arise from coupled disturbances in lipid handling, insulin sensitivity, mitochondrial function, immune signaling, gut-liver communication, and fibrogenesis. Plant extracts and isolated compounds can act across several of these processes, but variable composition, uncertain active constituents, and limited oral exposure constrain their development. Purpose: This review compares source-plant extracts, defined bioactive compounds, and plant-derived exosome-like nanoparticles (PELNs) as related but distinct forms of plant pharmacology for MASLD/MASH. Study design: A narrative review integrating PELNs, source-plant extracts, isolated compounds, and clinical studies.Methods: A structured two-stage search of PubMed, Web of Science, Scopus, and Embase was conducted to identify evidence relevant to MASLD/MASH. Results: Evidence from the corresponding plants supports effects on lipogenesis, fatty-acid oxidation, oxidative stress, inflammasome signaling, intestinal barrier function, gut microbiota, hepatocyte injury, and hepatic stellate-cell activation. Direct PELN evidence is much narrower: 12 preclinical studies cover 11 plant sources, and most by a single report. Selected PELNs have shown intestinal, metabolic, inflammatory, or antifibrotic activity, but vesicle identity, functional cargo, oral fate, and tissue exposure are often incompletely defined. Engineered vesicle hybrids may improve cargo loading or distribution, although their pharmacology cannot be attributed to native PELNs alone. Clinical studies have examined several source-plant preparations, but no purified PELN formulation has entered clinical evaluation for MASLD/MASH. Conclusion:Progress will require standardized preparation, separation of vesicle-mediated effects from co-isolated constituents, causal cargo validation, quantitative biodistribution, direct comparison with source extracts and free compounds, and repeated-dose safety testing. At present, PELNs remain a preclinical research platform rather than an established therapeutic class.